This website is intended for healthcare professionals only
User log in




Trial log in
  

Targets for glycaemic control in type 2 diabetes


This promotional module has been initiated, funded and reviewed by Boehringer Ingelheim. The content of this industry-supported learning activity has been generated by Practice Nurse.

INTRODUCTION

Increasingly, day-to-day management of people with type 2 diabetes falls to general practice nurses (GPNs).1 It is therefore important that they are familiar with the latest guidelines, and understand how to apply the recommendations to their individual patients. This includes recognising how to determine appropriate targets (for example, for blood glucose control) in each individual case.

This module will help improve awareness of the role of adequate blood glucose control in the prevention of the complications of diabetes

LEARNING OBJECTIVES

On completion of this module, the GPN will be aware of:

  • Current targets as recommended in the recent national and international guidelines
  • The importance of agreeing targets with individual patients
  • When to intensify drug treatment to achieve targets
  • When to consider relaxing the target (on a case-by-case basis)
  • The importance of good blood glucose control for the prevention of complications.

This module is one of a series of five. Others in the series are:

  • Tailoring therapy to the individual patient
  • Short-term complications of type 2 diabetes
  • Renal considerations in patients with type 2 diabetes
  • Cardiovascular considerations in patients with type 2 diabetes

This resource is provided at an intermediate level. Read the article and answer the self-assessment questions, and reflect on what you have learned.

Complete the resource to obtain a certificate to include in your revalidation portfolio. You should record the time spent on this resource in your CPD log.

Job Code: PC-GB-102830

Date of preparation: February 2021


You can sign up here to receive and manage your electronic communications from Boehringer Ingelheim and its agents acting on its behalf, about BI's products, services and events.

Click here for Trajenta (linagliptin) Prescribing Information

Click here for Jardiance (empagliflozin) Prescribing Information

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).